OCTS EU 2022

OCTS EU 2022

Bringing together cell therapy specialists to develop more efficacious therapies and efficient vein-to-vein processes

Download Past Agenda
Amsterdam, The Netherlands
2-3 November, 2022

“The event was very interesting and well organised. I liked the mixture of scientific talks with updates on current developments alongside more practical 'logistical and regulatory' issues one encounters in the daily life of delivering these treatments to patients in clinical trials.”

Bilyana Popova, Senior Trial Co-ordinator, UCL

Why Attend

The Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations, townhall meetings, roundtable sessions and coffee break style networking.

The Global Onco Cell Therapy Summit provides a platform for information sharing to enable the discovery, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma, biotechs and academia. The summit will address the research, regulatory, logistical and technical challenges that are holding back the field.

Delve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through:

  • Meeting efficacies and safety targets as well as the scale of demands.
  • Discovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.
  • Overcoming the challenging in scale up and automation of manufacturing
  • Round table discussions on vectors and the promise of non-viral approaches.
  • Reimbursment strategies and their link to the latest developments in safety trials and regulatory standards 

Whilst bringing together the key decision makers for oncological cell therapies, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments.

Mission Statement

With 5 CAR-T therapies now approved, the cell therapy market is starting to move through its nascent stages. As of the start of 2021, there are another 23 candidates in phase III clinical trials. As the competition between approved cell therapies becomes available to patients, differentials in price and efficacy become front of mind.

The Onco Cell Therapy Summit returns to the EU in 2022 to address issues in scale-up and out of next-generation therapies and explore the translation of R&D through the clinic to revolutionize patient outcomes in oncology.

LEADING INDUSTRY MINDS

 

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma
 

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity
 

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany
 

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva
 

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD
 

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics
 

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma
 

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit
 

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix
 

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden
 

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute
 

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate
 

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics
 

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic
 

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda
 

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology
 

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics
 

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences
 

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences
 

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem
 

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London
 

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT
 

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University
 

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy
 

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio
 

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB
 

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University
 

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics
 

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics
 

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr.

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations.  He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences.  He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.

 

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania
 

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

WHO WILL BE THERE

45%
Biotech & Pharmaceutical Companies
15%
Cell Therapy Academics and Clinicians
20%
Biotechology Companies (Equipment, Materials & Logistics)
20%
Service Providers & Consultants

Biotech & Pharmaceutical Companies

Cell Therapy Academics and Clinicians

Biotechology Companies (Equipment, Materials & Logistics)

Service Providers & Consultants

PAST ATTENDEES

2022 Agenda

The OCTS EU 2022 Agenda is launching soon. Come back to download in the New Year!

In the meantime, take a look at some of our industry-leading speakers from our Past Summits...

Past Speakers of OCTS Summits


Browse Top Industry Speakers

POSTER SUBMISSION

Are you looking to showcase your recent work to the OCTS community?

Our dedicated poster session is the perfect way to get your research noticed. To present a poster, you need to register as a delegate. Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

The poster abstract submission deadline is on 3rd June.

Abstracts received after this time may not be accepted, so please submit your abstract as soon as possible! Academics that submit a poster abstract before 3rd June get a 40% discount!

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

If you have any questions, please contact [email protected]

Click HERE to make a submission.

TESTIMONIALS

Resources

Download Resource

2021 Expertise Partners

2021 Tech Showcase Partner

2021 Event Partners

2021 Media Partners

Become a Partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Thursday, April 7, 2022 to Friday, June 10, 2022
Pre-Launch Tier 1 - Academics
£499
+ VAT Ends 10th June
This pass will give you access to all live content, 1-2-1 meetings and on-demand content across the 2 day event.
You will also have the ability to book 1-2-1 meetings throughout the 2 days that the event is taking place.
To increase your brand presence, contact Nathan Edwards, [email protected]
Thursday, April 7, 2022 to Friday, June 10, 2022
Pre-Launch Tier 2 - Biotech & Pharma
£999
+ VAT Ends 10th June
This pass will give you access to all live content, 1-2-1 meetings and on-demand content across the 2 day event.
You will also have the ability to book 1-2-1 meetings throughout the 2 days that the event is taking place.
To increase your brand presence, contact Nathan Edwards, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us